Heidelberg Pharma
Manufacturing · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Gregor-mendel-strasse 22, Ladenburg, 685...Phone Number
+49 620310090Website
www.heidelberg-pharma.comRevenue
<$5 MillionStock Symbol
HPHAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Heidelberg Pharma
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which isRead more
Heidelberg Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Heidelberg Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Heidelberg Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Heidelberg Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Heidelberg Pharma
Check out if Heidelberg Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Heidelberg Pharma launches new products
Earning: See what the market has to say on Heidelberg Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Heidelberg Pharma has new funding data
Heidelberg Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Heidelberg Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Heidelberg Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Heidelberg Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Heidelberg Pharma.
Heidelberg Pharma financials insights
Gather financial insights about Heidelberg Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Private Equity
$35.8M
2024
Debt
$115M
Heidelberg Pharma Tech Stack
A closer look at the technologies used by Heidelberg Pharma
See more technologies
Most Recent Scoops
Open Position
Hiring Plans
Heidelberg Pharma has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Executive Move
Executive Moves, Board of Directors
Heidelberg Pharma News & Media
Heidelberg Pharma AG Announces Chief Executive Officer Changes, Effective 24 November 2025
Heidelberg Pharma AG announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as new...Heidelberg Pharma Misses Out on Royalty Payment, Plans 75% Workforce Cut - BioSpace
The company was awaiting $70 million from HealthCare Royalty but missed an agreed-upon payment condition.Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Heidelberg Pharma
Sign Up For FreeTo access detailed company insights
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP... Read More
